Publications
Ferguson ID, Patiño-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL, Martin TG, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey AD, Mullins RD, Eyquem J, Wells JA, Wiita AP. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nature communications. 2022. PMID: 35840578
Soe MH, Chiang JM, Flavell RR, Khanafshar E, Mendoza L, Kang H, Liu C. Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology. The Journal of clinical endocrinology and metabolism. 2022. PMID: 35556126
Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA. The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study. Annals of surgical oncology. 2022. PMID: 35810223
Idossa D, Friedlander T, Paller CJ, Ryan CJ, Borno HT. Case Report: Clinical Characteristics and Outcomes of HIV Positive Patients With Metastatic Prostate Cancer Treated With Immunotherapy: A Case Series and Literature Review. Frontiers in oncology. 2022. PMID: 35875156
Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA. ASO Visual Abstract: The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer-A National Cancer Database Study. Annals of surgical oncology. 2022. PMID: 35798896
Morgan G, Agarwal N, Choueiri TK, Dizon DS, Hamilton EP, Markham MJ, Lewis M, Prowell TM, Rugo HS, Subbiah V, West HL. The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. Cancer discovery. 2022. PMID: 35791692
Davies FE, Pawlyn C, Usmani SZ, San-Miguel JF, Einsele H, Boyle EM, Corre J, Auclair D, Cho HJ, Lonial S, Sonneveld P, Stewart AK, Bergsagel PL, Kaiser MF, Weisel K, Keats JJ, Mikhael JR, Morgan KE, Ghobrial IM, Orlowski RZ, Landgren CO, Gay F, Caers J, Chng WJ, Chari A, Walker BA, Kumar SK, Costa LJ, Anderson KC, Morgan GJ. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood cancer discovery. 2022. PMID: 35653112
Allemann-Su YY, Vetter M, Koechlin H, Paul SM, Cooper BA, Oppegaard K, Melisko M, Levine JD, Conley Y, Miaskowski C, Katapodi MC. Pre-Surgery Demographic, Clinical, and Symptom Characteristics Associated with Different Self-Reported Cognitive Processes in Patients with Breast Cancer. Cancers. 2022. PMID: 35805053
Chen H, Diolaiti ME, O'Leary PC, Rojc A, Krogan NJ, Kim M, Ashworth A. A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor. Molecular cancer therapeutics. 2022. PMID: 35439318
Vidula N, Yau C, Rugo H. Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer. Breast cancer research and treatment. 2022. PMID: 35789445
Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. 2022. PMID: 35798016
Munigala S, Gardner TB, O'Reilly EM, Fernández-Del Castillo C, Ko AH, Pleskow D, Vollmer CM, Searle NA, Bakelman D, Holt JM, Gelrud A. Helping Patients Understand Pancreatic Cancer Using Animated Pancreas Patient Education With Visual Formats of Learning. Volume 51 of Issue 6 Pancreas. 2022. PMID: 36206469
Tempero M. Failure Doesn't Feel Good! Journal of the National Comprehensive Cancer Network : JNCCN. 2022. PMID: 35830894
Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J, ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA oncology. 2022. PMID: 35552364
Nanjo S, Wu W, Karachaliou N, Blakely CM, Suzuki J, Chou YT, Ali SM, Kerr DL, Olivas VR, Shue J, Rotow J, Mayekar MK, Haderk F, Chatterjee N, Urisman A, Yeo JC, Skanderup AJ, Tan AC, Tam WL, Arrieta O, Hosomichi K, Nishiyama A, Yano S, Kirichok Y, Tan DS, Rosell R, Okimoto RA, Bivona TG. Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. The Journal of clinical investigation. 2022. PMID: 35579943
Nixon AB, Halabi S, Liu Y, Starr MD, Brady JC, Shterev I, Luo B, Hurwitz HI, Febbo PG, Rini BI, Beltran H, Small EJ, Morris MJ, George DJ. Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance). Clinical cancer research : an official journal of the American Association for Cancer Research. 2022. PMID: 34965953
Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer Research Communications. 2022. PMID: 36923283
Nixon AB, Sibley AB, Liu Y, Hatch AJ, Jiang C, Mulkey F, Starr MD, Brady JC, Niedzwiecki D, Venook AP, Baez-Diaz L, Lenz HJ, O'Neil BH, Innocenti F, Meyerhardt JA, O'Reilly EM, Owzar K, Hurwitz HI. Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). Clinical cancer research : an official journal of the American Association for Cancer Research. 2022. PMID: 34965954
Morgan J, DeBoer RJ, Bigirimana JB, Nguyen C, Ruhangaza D, Paciorek A, Mugabo F, Villaverde C, Nsabimana N, Bihizimana P, Umwizerwa A, Lehmann LE, Shulman LN, Shyirambere C. A Ten-Year Experience of Treating Chronic Myeloid Leukemia in Rural Rwanda: Outcomes and Insights for a Changing Landscape. JCO global oncology. 2022. PMID: 35839427
Kwon H, Schafer JM, Song NJ, Kaneko S, Li A, Xiao T, Ma A, Allen C, Das K, Zhou L, Riesenberg B, Chang Y, Weltge P, Velegraki M, Oh DY, Fong L, Ma Q, Sundi D, Chung D, Li X, Li Z. Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer. Science immunology. 2022. PMID: 35420889